Buscar este blog

lunes, 31 de enero de 2011

NATALIZUMAB: Algunas Revisiones y artìculos relevantes

PMC Results
Items 1 - 20 of 367

Effects of Natalizumab Treatment on Foxp3+ T Regulatory Cells
Max-Philipp Stenner, Anne Waschbisch, Dorothea Buck, Sebastian Doerck, Hermann Einsele, Klaus V. Toyka, and Heinz Wiendl
PLoS ONE. 2008; 3(10): e3319. Published online 2008 October 6. doi: 10.1371/journal.pone.0003319.
PMCID: PMC2553177

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function
B O. Khatri, S Man, G Giovannoni, A P. Koo, J-C Lee, B Tucky, F Lynn, S Jurgensen, J Woodworth, S Goelz, P W. Duda, M A. Panzara, R M. Ransohoff, and R J. Fox
Neurology. 2009 February 3; 72(5): 402–409. doi: 10.1212/01.wnl.0000341766.59028.9d.
PMCID: PMC2677532

Natalizumab for the treatment of relapsing multiple sclerosis
Richard A Rudick and Michael A Panzara
Biologics. 2008 June; 2(2): 189–199. Published online 2008 June.
PMCID: PMC2721353

Natalizumab in the Treatment of Multiple Sclerosis
Özgür Yaldizli and Norman Putzki
Ther Adv Neurol Disord. 2009 March; 2(2): 115–128. doi: 10.1177/1756285608101861.
PMCID: PMC3002624

Natalizumab: A new treatment for relapsing remitting multiple sclerosis
Michael Hutchinson
Ther Clin Risk Manag. 2007 June; 3(2): 259–268. Published online 2007 June.
PMCID: PMC1936307

Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells
P Kivisäkk, B C. Healy, V Viglietta, F J. Quintana, M A. Hootstein, H L. Weiner, and S J. Khoury
Neurology. 2009 June 2; 72(22): 1922–1930. doi: 10.1212/WNL.0b013e3181a8266f.
PMCID: PMC2690969

Reactivation of Human Herpesvirus-6 in Natalizumab Treated Multiple Sclerosis Patients
Karen Yao, Susan Gagnon, Nahid Akhyani, Elizabeth Williams, Julie Fotheringham, Elliot Frohman, Olaf Stuve, Nancy Monson, Michael K. Racke, and Steven Jacobson
PLoS ONE. 2008; 3(4): e2028. Published online 2008 April 30. doi: 10.1371/journal.pone.0002028.
PMCID: PMC2323568

Natalizumab in the treatment of multiple sclerosis
Brandon A Brown
Ther Clin Risk Manag. 2009; 5: 585–594. Published online 2009 August 3.
PMCID: PMC2724189

Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy
O Stüve, P D. Cravens, E M. Frohman, J T. Phillips, G M. Remington, G von Geldern, S Cepok, M P. Singh, J W. Cohen Tervaert, M De Baets, D MacManus, D H. Miller, E W. Radü, E M. Cameron, N L. Monson, S Zhang, R Kim, B Hemmer, and M K. Racke
Neurology. 2009 February 3; 72(5): 396–401. doi: 10.1212/01.wnl.0000327341.89587.76.
PMCID: PMC2677530

Natalizumab in the treatment of Crohn's disease
Danila Guagnozzi and Renzo Caprilli
Biologics. 2008 June; 2(2): 275–284. Published online 2008 June.
PMCID: PMC2721358

Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab
Halvard Bonig, Annette Wundes, Kai-Hsin Chang, Sylvia Lucas, and Thalia Papayannopoulou
Blood. 2008 April 1; 111(7): 3439–3441. Prepublished online 2008 January 14. doi: 10.1182/blood-2007-09-112052.
PMCID: PMC2275012

An evidence-based review of natalizumab therapy in the management of Crohn's disease
Raja GR Edula and Michael F Picco
Ther Clin Risk Manag. 2009; 5: 935–942. Published online 2009 November 29.
PMCID: PMC2789688

Treatment of refractory epilepsy with natalizumab in a patient with multiple sclerosis. Case report
Stefano Sotgiu, Maria R Murrighile, and Gabriela Constantin
BMC Neurol. 2010; 10: 84. Published online 2010 September 23. doi: 10.1186/1471-2377-10-84.
PMCID: PMC2954970

Anti-adhesion molecule therapy for inflammatory bowel disease
Subrata Ghosh and Remo Panaccione
Therap Adv Gastroenterol. 2010 July; 3(4): 239–258. doi: 10.1177/1756283X10373176.
PMCID: PMC3002582

Natalizumab in pediatric multiple sclerosis patients
E. Ann Yeh and Bianca Weinstock-Guttman
Ther Adv Neurol Disord. 2010 September; 3(5): 293–299. doi: 10.1177/1756285610381526.
PMCID: PMC3002661

Quantitative risk-benefit analysis of natalizumab
J P. Thompson, K Noyes, E R. Dorsey, S R. Schwid, and R G. Holloway
Neurology. 2008 July 29; 71(5): 357–364. doi: 10.1212/01.wnl.0000319648.65173.7a.
PMCID: PMC2676947

Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy
Tarek A. Yousry, Eugene O. Major, Caroline Ryschkewitsch, Gary Fahle, Steven Fischer, Jean Hou, Blanche Curfman, Katherine Miszkiel, Nicole Mueller-Lenke, Esther Sanchez, Frederik Barkhof, Ernst-Wilhelm Radue, Hans R. Jäger, and David B. Clifford
N Engl J Med. Author manuscript; available in PMC 2007 July 30.
PMCID: PMC1934511
Published in final edited form as: N Engl J Med. 2006 March 2; 354(9): 924–933. doi: 10.1056/NEJMoa054693.
Manuscript: | Abstract | Full Text | PDF–104K |

Remitting–relapsing multiple sclerosis patient refractory to conventional treatments and bone marrow transplantation who responded to natalizumab
Athanasia Mouzaki, Maria Koutsokera, Zoe Dervilli, Maria Rodi, Dimitra Kalavrizioti, Nikolaos Dimisianos, Ioannis Matsoukas, and Panagiotis Papathanasopoulos
Int J Gen Med. 2010; 3: 313–320. Published online 2010 October 5. doi: 10.2147/IJGM.S13648.
PMCID: PMC2962327

GLANCE: Results of a phase 2, randomized, double-blind, placebo-controlled study
A D. Goodman, H Rossman, A Bar-Or, A Miller, D H. Miller, K Schmierer, F Lublin, O Khan, N M. Bormann, M Yang, M A. Panzara, A W. Sandrock, and For the GLANCE Investigators
Neurology. 2009 March 3; 72(9): 806–812. doi: 10.1212/01.wnl.0000343880.13764.69.
PMCID: PMC2821836

Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report
Stylianos Gatzonis and Anna Siatouni
J Med Case Reports. 2009; 3: 8955. Published online 2009 August 27. doi: 10.4076/1752-1947-3-8955.
PMCID: PMC2827173

No hay comentarios: